European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)
KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then... Read more.
Evercore Reports Third Quarter 2025 Results; Quarterly Dividend of $0.84 Per Share
NEW YORK–(BUSINESS WIRE)–Evercore Inc. (NYSE: EVR): Third Quarter Results Year to Date Results U.S. GAAP Adjusted ... Read more.
Valero Energy Corporation Announces CFO Transition
Jason Fraser to Retire as CFO December 31 Homer Bhullar to Assume CFO Position SAN ANTONIO–(BUSINESS WIRE)–Valero Energy Corporation (NYSE: VLO, “Valero”)... Read more.
NiSource announces third quarter results
Reaffirming upper half of 2025 non-GAAP adjusted EPS guidance Introducing 2026 non-GAAP consolidated adjusted EPS guidance Extending base plan expected non-GAAP... Read more.
Valero Energy Corporation Declares Regular Cash Dividend on Common Stock
SAN ANTONIO–(BUSINESS WIRE)–The Board of Directors of Valero Energy Corporation (NYSE: VLO, “Valero”) has declared a regular quarterly... Read more.
Ares Direct Lending Raises $1.5 Billion for Specialty Healthcare Strategy
NEW YORK–(BUSINESS WIRE)–Ares Management Corporation (“Ares”) (NYSE: ARES), a leading global alternative investment manager, announced... Read more.
Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors
LONDON & NEW YORK–(BUSINESS WIRE)–$CMPS #Biotech–Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient... Read more.
ITT Reports 2025 Third Quarter Earnings Per Share (EPS) of $1.62, Adjusted EPS of $1.78; Raising Full Year Guidance
Generated ~$1 billion in revenue, up 13% (6% organic), driven by aerospace and defense, share gains in pump projects and automotive and pricing 18.0% operating margin... Read more.
Cadre Holdings to Acquire TYR Tactical
Leading Provider of Plate Carriers, Vests, Hard Armor, and Shields to Tactical Teams Expected to be Immediately Accretive and Advances Strategic Focus on Mission-Critical... Read more.
Sonoma Biotherapeutics Announces Positive Interim Safety and Efficacy Data from Phase 1 REGULATE-RA Study of SBT-77-7101 in Refractory Rheumatoid Arthritis
Favorable early safety profile with preliminary clinical and mechanistic evidence of therapeutic activity in refractory rheumatoid arthritis Data to be presented... Read more.